BR100 Decreased By (-1.39%)
BR30 Decreased By (-1.72%)
KSE100 Decreased By (-1.3%)
KSE30 Decreased By (-1.25%)
AGHA 7.92 Decreased By ▼ -0.17 (-2.1%)
BECO 5.20 Decreased By ▼ -0.07 (-1.33%)
BML 59.25 Decreased By ▼ -0.13 (-0.22%)
BOP 33.68 Decreased By ▼ -0.51 (-1.49%)
CNERGY 9.81 Increased By ▲ 0.19 (1.98%)
CSIL 5.42 Decreased By ▼ -0.08 (-1.45%)
FCCL 53.52 Decreased By ▼ -0.63 (-1.16%)
FFL 16.68 Decreased By ▼ -0.16 (-0.95%)
FNEL 1.21 Decreased By ▼ -0.02 (-1.63%)
KEL 7.35 Decreased By ▼ -0.24 (-3.16%)
KOSM 5.61 Decreased By ▼ -0.07 (-1.23%)
LOTCHEM 29.11 Decreased By ▼ -1.32 (-4.34%)
MLCF 95.50 Decreased By ▼ -2.66 (-2.71%)
NBP 204.35 Decreased By ▼ -4.44 (-2.13%)
NCPL 58.24 Decreased By ▼ -1.37 (-2.3%)
NPL 67.79 Decreased By ▼ -2.08 (-2.98%)
OGDC 317.94 Decreased By ▼ -5.42 (-1.68%)
PACE 10.71 Decreased By ▼ -0.36 (-3.25%)
PAEL 41.83 Decreased By ▼ -0.42 (-0.99%)
PIBTL 16.50 Decreased By ▼ -0.32 (-1.9%)
PPL 219.74 Decreased By ▼ -4.99 (-2.22%)
PRL 44.59 Increased By ▲ 2.94 (7.06%)
PTC 70.77 Decreased By ▼ -0.35 (-0.49%)
SSGC 28.93 Decreased By ▼ -0.38 (-1.3%)
TBL 9.84 Decreased By ▼ -0.12 (-1.2%)
TELE 8.76 Decreased By ▼ -0.23 (-2.56%)
TPL 16.45 Decreased By ▼ -0.07 (-0.42%)
TPLP 12.10 Decreased By ▼ -0.67 (-5.25%)
TREET 22.80 Decreased By ▼ -0.26 (-1.13%)
TRG 60.03 Decreased By ▼ -0.42 (-0.69%)
World

German court suspends mRNA patent trial against BioNTech

Published Updated
By

DUESSELDORF: A German court on Thursday suspended a patent trial against BioNTech over the use of mRNA technology in the COVID-19 vaccine developed by the German company together with its US partner Pfizer.

The Duesseldorf regional court said it needed further clarification and suspended the case, brought by BioNTech competitor CureVac, pending a decision by the federal patent court on a lawsuit filed by BioNTech.

Germany’s Scholz ‘not convinced’ about tariffs on Chinese EVs

It had asked the higher court to review the validity of CureVac’s intellectual property rights. A decision is expected in December.

Comments

Comments are closed for this article.